Sugammadex dosing based on ideal or actual body weight in underweight patients.

JRCT ID: jRCT1031230452

Registered date:19/11/2023

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Patients undergoing general anesthesia
• Date of first enrollment: 19/11/2023
• Target sample size: 32
• Study type: Interventional
• Intervention(s): Sugammadex will be administered in two doses: a real-weight group and an ideal-weight group.

Outcome(s)

• Primary Outcome: Time from sugammadex administration to TOFR=90%.

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

BMI below 18.5
ASA-PS= 1-3

Exclude criteria

ppatient who is allergic to muscle relaxants
patient who has neuromuscular diseases
patient who has moderate to severe liver function failure
Patients with hypoalbuminemia
Patients taking medications that affect the muscle relaxant effect
Patients who are deemed inappropriate as research subjects by the principal investigator

Related Information

• Primary Sponsor: Sato Hanae